Lab
Morristown Hamblen Hospital Association
Morristown Hamblen Hospital Association was paid $17.83M by Medicaid between Jan 2018 and Dec 2024, across 142 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoMORRISTOWN HAMBLEN HOSPITAL ASSOCIATION
MORRISTOWN, TN 37814
MORRISTOWN, TN 37814
33aNPI1912997024assigned 10/28/2005
33bProvider typeClinical Medical Laboratory
28Total paid$17.83M
24GClaims470,851
24DCodes billed142
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Tennessee
Rank by total paid#8 of 70
Median peer was paid$141K
This provider vs. median126×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 60,869 | $1.59M | |
| 2019 | 73,265 | $2.67M | |
| 2020 | 54,785 | $2.14M | |
| 2021 | 65,885 | $2.45M | |
| 2022 | 73,467 | $2.77M | |
| 2023 | 82,203 | $3.21M | |
| 2024incomplete | 60,377 | $3.01M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 27,027 | 25,063 | $6.00M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 33,066 | 31,379 | $4.68M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 10,358 | 9,462 | $2.80M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 14,877 | 13,377 | $478K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 5,655 | 5,353 | $402K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.1% | 4,235 | 1,894 | $379K |
| G0378 | Hospital observation service, per hour | 2.1% | 1,974 | 1,223 | $367K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.8% | 14,414 | 13,587 | $317K |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.8% | 616 | 599 | $314K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 60,734 | 49,893 | $255K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 12,644 | 9,603 | $199K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 429 | 406 | $144K |
130 more codes
| 80053 | Comprehensive metabolic panel | <1% | 42,783 | $117K |
| 87276 | <1% | 15,127 | $90K | |
| 84484 | <1% | 6,861 | $90K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 35,493 | $87K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,410 | $83K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,647 | $72K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,821 | $72K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,834 | $60K |
| 87275 | <1% | 15,126 | $59K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,423 | $57K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,226 | $49K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 683 | $39K |
| 83690 | <1% | 8,977 | $39K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 663 | $37K |
| 97597 | <1% | 1,206 | $32K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,549 | $31K |
| 93458 | <1% | 59 | $28K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,969 | $27K |
| 77334 | <1% | 174 | $26K | |
| 77386 | <1% | 373 | $25K | |
| 80061 | Lipid panel | <1% | 2,345 | $24K |
| 77336 | <1% | 811 | $24K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 484 | $23K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 292 | $21K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,581 | $19K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,902 | $17K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 314 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,569 | $15K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 835 | $14K |
| 84703 | <1% | 2,527 | $14K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,764 | $13K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 251 | $13K |
| 83735 | <1% | 3,293 | $11K | |
| 87081 | <1% | 3,228 | $10K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,909 | $10K |
| 81001 | <1% | 11,857 | $10K | |
| 96367 | <1% | 450 | $9K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 14 | $7K |
| 77300 | <1% | 95 | $6K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 533 | $6K |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 158 | $5K |
| 59025 | Fetal non-stress test | <1% | 105 | $4K |
| 82728 | <1% | 1,349 | $4K | |
| 86850 | <1% | 229 | $4K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 14 | $4K |
| 81003 | <1% | 5,702 | $4K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 275 | $4K |
| 84466 | <1% | 1,350 | $3K | |
| 84439 | <1% | 1,642 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,161 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,481 | $3K |
| 86900 | <1% | 153 | $3K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 43 | $3K |
| 87807 | <1% | 549 | $3K | |
| 82077 | <1% | 755 | $3K | |
| 85027 | <1% | 963 | $3K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 68 | $2K |
| 97161 | <1% | 32 | $2K | |
| 74018 | <1% | 97 | $2K | |
| 85610 | <1% | 1,469 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 55 | $2K |
| 96417 | <1% | 67 | $2K | |
| 83540 | <1% | 1,382 | $2K | |
| 81025 | <1% | 716 | $2K | |
| 84100 | <1% | 924 | $2K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 14 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 165 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 852 | $1K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 44 | $1K |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 27 | $1K |
| 87040 | <1% | 137 | $1K | |
| 43450 | <1% | 14 | $1K | |
| 82140 | <1% | 159 | $1K | |
| 82607 | <1% | 419 | $1K | |
| 86901 | <1% | 153 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 50 | $992.05 |
| 82550 | <1% | 434 | $975.68 | |
| 82805 | <1% | 63 | $916.40 | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 15 | $898.79 |
| 83605 | <1% | 255 | $809.38 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 63 | $793.88 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 63 | $793.87 |
| 83525 | <1% | 108 | $761.56 | |
| 85730 | <1% | 255 | $723.20 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 451 | $594.01 |
| 82746 | <1% | 169 | $590.84 | |
| 76775 | <1% | 13 | $525.30 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 210 | $521.58 |
| 82533 | <1% | 372 | $494.70 | |
| 80076 | <1% | 175 | $488.20 | |
| 82553 | <1% | 298 | $356.73 | |
| 86140 | <1% | 334 | $333.34 | |
| 96523 | <1% | 32 | $318.64 | |
| 77417 | <1% | 91 | $317.98 | |
| 83880 | <1% | 49 | $283.60 | |
| 82330 | <1% | 55 | $275.44 | |
| 87205 | <1% | 46 | $159.98 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 15 | $122.87 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 27 | $121.86 |
| 86803 | <1% | 14 | $106.25 | |
| 85379 | <1% | 12 | $97.59 | |
| 85652 | <1% | 35 | $90.89 | |
| 87186 | <1% | 40 | $84.80 | |
| 83615 | <1% | 351 | $82.68 | |
| 87070 | <1% | 51 | $59.10 | |
| 88312 | <1% | 364 | $39.20 | |
| 82668 | <1% | 33 | $38.67 | |
| 86592 | <1% | 15 | $29.60 | |
| 82378 | <1% | 18 | $26.02 | |
| 87077 | <1% | 50 | $25.48 | |
| 84153 | <1% | 13 | $25.24 | |
| 82043 | <1% | 12 | $11.91 | |
| 82570 | <1% | 12 | $10.65 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,211 | $3.24 |
| A9270 | Non-covered item or service | <1% | 2,781 | $0.02 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 152 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 451 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 88 | $0.00 |
| 85014 | 0% | 29 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 81 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 107 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 85 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 20 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 586 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 154 | $0.00 |
| 85018 | 0% | 29 | $0.00 | |
| C1769 | Guide wire | 0% | 111 | $0.00 |
| 83090 | 0% | 15 | $0.00 | |
| 83921 | 0% | 14 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 64 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARRINGER, RICK (VP REVENUE CYCLE)
Parent organizationCOVENANT HEALTH
| Provider | Location | Paid |
|---|---|---|
| Parkwest Medical Center | Knoxville, TN | $29.88M |
| Fort Sanders Regional Medical Center | Knoxville, TN | $26.76M |
| Leconte Medical Center | Sevierville, TN | $19.05M |
| Methodist Medical Center | Oak Ridge, TN | $11.32M |
| Roane County Medical Center | Harriman, TN | $9.24M |
| Cumberland Medical Center, INC. | Crossville, TN | $6.06M |
| Fort Loudoun Medical Center | Lenoir City, TN | $5.86M |
| Claiborne Medical Center | Tazewell, TN | $3.41M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.